ClinicalTrials.gg
CompletedNCT03050723FLASH 1Updated Dec 9, 2024

Safety and Performance of Princess® FILLER for the Treatment of Facial Lipoatrophy, Asymmetry or Scars

An interventional study of Princess® FILLER in Facial Lipoatrophy, Morphological Asymmetry of the Face and Debilitating Scars, sponsored by Croma-Pharma GmbH. Completed at 3 sites in Austria. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2024-12-09.

Sponsored by Croma-Pharma GmbH · Not applicable, Interventional, and Other

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
53
Allocation
Not applicable
Ages
18 Years and older
Sex
All
01

Study summary

In this study, eligible patients with the medical indications (facial lipoatrophy, morphological asymmetry of the face, or debilitating scars) will be treated with Princess® FILLER, and then will return for follow-up assessments 2, 4 and 24 weeks after the treatment. A touch-up treatment may be done 2 weeks after the treatment.

02

Conditions studied

  • Facial Lipoatrophy
  • Morphological Asymmetry of the Face
  • Debilitating Scars

Browse trials for

03

In context

Cicatrix

613 studies on the registry are indexed under Cicatrix; 114 are open to participants now.

This study's enrollment of 53 is above the median of 40 across 514 interventional studies indexed under Cicatrix.

Browse Cicatrix studies →

Lead sponsor

Croma-Pharma GmbH is the lead sponsor of 26 studies on the registry; 2 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Male or female 18 years of age or older.
  • Presence of a defect, which in the opinion of the Investigator can be corrected by a dermal filler, and is caused by: ° Facial lipoatrophy of moderate severity, or

    • Morphological asymmetry of the face, or
    • One or more debilitating scars on the face.
  • Willingness to abstain from any cosmetic or surgical procedures in the treatment area for the duration of the clinical investigation.
  • Willingness to take part in the clinical investigation as evidenced by a personally signed .

Exclusion criteria

Exclusion Criteria:

  • Pregnancy, breastfeeding, or unwillingness to use throughout the clinical investigation (for women of only).
  • History of allergic reaction or to hyaluronic acid.
  • History or presence of any or connective tissue disease, or current treatment with immune therapy.
  • Presence of silicone implant or other non-absorbable tissue filler in the area targeted for intervention, or pre-treatment with any hyaluronic acid filler within the last 6 months.
  • Presence of infectious, inflammatory, or proliferative lesions in the area targeted for intervention.
  • Treatment with anticoagulant or antiplatelet drugs
  • Any disease or condition which, in the Investigator's opinion, represents a safety risk for participation in the study
  • Current participation in another clinical trial, or previous treatment with any drug/device within 30 days prior to enrolment
  • Institutionalized persons with legally limited civil rights
Terms in these criteria, in plain language(6)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Not applicable
Primary purpose
Other
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
53 participants (actual)

Study arms

  • Other
    Princess® FILLER

    Device: Princess® FILLER

Interventions

  • DevicePrincess® FILLER

    Princess® FILLER injections up to 10 ml applied to the eligible subjects at the baseline visit, and the touch-up visit, if applicable.

06

What researchers measure

Primary outcomes

  1. 6-point scale for clinical response

    The proportion of patients with successful treatment outcome at the Week 4 visit based on the Investigator's opinion, where success is defined as excellent, good, or moderate correction of the defect

    Time frame: Week 4

07

Study locations

3 sites
  • Medical University Graz
    Graz, Austria
  • MÄZ WIEN (Medizinisch Ästhetisches Zentrum Wien)
    Wien, Austria
  • Ordination Dr. Benjamin Gehl
    Wien, Austria
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Nov 2016 to primary completion in Jul 2017, 7 months.

Of 33 industry-sponsored interventional studies with no phase under Cicatrix, half reached primary completion within 9 months of starting (the median), counting those still running; a quarter within 8 and three quarters within 20. This study's 7 months is below that.

Counting every sponsor, half of 207 studies reached it within 18 months; a quarter within 8 and three quarters within 35.

How these figures are worked out, and which studies are left out of them.

Registered
Feb 9, 2017
First posted
Feb 13, 2017
StartActual
Nov 20, 2016
Primary completionActual
Jul 17, 2017
CompletionActual
Jan 16, 2018
Last update
Dec 9, 2024
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Dec 9, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT03050723
Lead sponsor
Croma-Pharma GmbH
Responsible party
Sponsor
First posted
Feb 13, 2017
Start date
Nov 20, 2016
Primary completion
Jul 17, 2017
Completion
Jan 16, 2018
Last update
Dec 9, 2024

Study contacts

Daisy Kopera, Prof.
principal investigator · Medical University Graz, Austria

Oversight

Data monitoring committee
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Dec 2024. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion